International Health Management Associates, Inc., Schaumburg, IL, USA.
Escherichia coli is the most important uropathogen. The Study for Monitoring Antimicrobial Resistance Trends program collected 1643 E. coli isolates in 2009-2010 from urinary tract infection (UTI) specimens of hospitalized patients in countries worldwide. Ertapenem and imipenem were the most active agents tested, inhibiting >98% of all E. coli phenotypes. Overall, 17.9% of isolates were extended-spectrum beta-lactamase (ESBL) producers. The highest ESBL rate was from the Asia/Pacific region (27.7%). Amikacin and piperacillin-tazobactam achieved 90% inhibition levels only for ESBL-negative isolates. Ciprofloxacin and levofloxacin were not effective for ESBL-positive isolates, with only 14.6% and 15.9% susceptible, respectively. These observations highlight the need for continued monitoring of susceptibility of E. coli isolated from hospitalized patients with UTIs.
Written by:
Hoban DJ, Nicolle LE, Hawser S, Bouchillon S, Badal R. Are you the author?
Reference: Diagn Microbiol Infect Dis. 2011 Aug;70(4):507-11.
doi: 10.1016/j.diagmicrobio.2011.03.021
PubMed Abstract
PMID: 21767706
UroToday.com Infections Section
